Pacemaker Implantation Postoperative Period for Bradyarrhythmia
Conditions
Interventions
Decoction Treatment Group:Standardized Western Medical Treatment plus QMXF Decoction Treatment Group
control:Standardized Western Medical Treatment
Granule Half-Dose Treatment Group:Standardized Western Medical Treatment plus Granule Half-Dose Treatment
Granule Normal Dose Treatment Group:Standardized Western Medical Treatment plus Granule Normal Dose Treatment
Sponsors
Guangzhou University of Chinese Medicine First Affiliated Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Meet the Western medical diagnostic criteria for bradyarrhythmia and have undergone permanent pacemaker implantation for more than 3 months. (2) Age between 18 and 80 years old, with no gender restrictions. (3) Good compliance, able to provide contact information, and can be followed up regularly. (4) Voluntarily participate, understand and sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Patients who have experienced pocket wound dehiscence, pocket skin necrosis, or pocket infection after pacemaker surgery. (2) Patients who require continuous administration of other antiarrhythmic drugs or drugs that significantly affect heart rate. (3) Patients with severe heart failure (NYHA functional class III-IV). (4) Patients with uncontrollable malignant arrhythmias or more than two complex arrhythmias. (5) Patients who have undergone or plan to undergo coronary revascularization treatment within 1 month or 3 months. (6) Patients with progressive acute coronary syndrome. (7) Patients with uncontrolled hypertension, with systolic blood pressure =180 mmHg and/or diastolic blood pressure =110 mmHg. (8) Patients in cardiogenic shock. (9) Patients with left ventricular outflow tract obstruction, myocarditis, aortic aneurysm, dissecting aortic aneurysm, or uncorrected heart valve disease causing significant hemodynamic changes. (10) Patients with a history of stroke (cerebral hemorrhage, subarachnoid hemorrhage, cerebral thrombosis, cerebral embolism, or stroke of undetermined type) or lower limb arterial disease within the last 6 months. (11) Patients with a history of active bleeding disorders within the last 6 months. (12) Patients with concurrent tumors, severe endocrine system diseases, mental disorders, severe primary diseases of the liver and kidneys, or severe hematopoietic system diseases. (13) Patients who are pregnant, have been pregnant within the last 6 months, are planning to become pregnant, have had a miscarriage, or are in the postpartum period including after childbirth, abortion, or delivery. (14) Patients with allergic constitutions or known allergies to treatment drugs. (15) Patients participating in other clinical trials. (16) Patients who, according to the investigator's judgment, cannot complete this study. (17) Patients with a life expectancy of less than 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pacing Ratio; | — |
Secondary
| Measure | Time frame |
|---|---|
| 6-Minute Walk Test;Traditional Chinese Medicine Syndrome Score;Perception Threshold, Catheter Impedance, 24-Hour Heart Rate Trend, Battery Status, Atrial Fibrillation Burden, Heart Failure Index;Minnesota Living with Heart Failure Questionnaire;Cardiovascular Events: New-Onset Heart Failure New-Onset Atrial Fibrillation Acute Exacerbation of Chronic Heart Failure; | — |
Countries
China
Contacts
Public ContactQingmin Chu
Guangzhou University of Chinese Medicine First Affiliated Hospital
Outcome results
None listed